Results 111 to 120 of about 728,357 (259)

Investigation of a broad‐spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient–drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Aims Daily broad‐spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad‐spectrum micronutrients in mental health care, there have not been any formal evaluations of potential interactions.
Bess M. Kew, Matthew P. Doogue, Richard McNeill, Mei Zhang, Julia J. Rucklidge, Christopher M. Frampton, Roger T. Mulder, Ben Beaglehole   +7 more
wiley   +1 more source

Editorial: Placebo Effect in Pain and Pain Treatment. [PDF]

Front Pain Res (Lausanne), 2022
Bernstein MH, Blease C, Vase L.
europepmc   +1 more source

Placebos and Placebo Effects [PDF]

Anaesthesia and Intensive Care, 2010
openaire   +2 more sources

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo, Ajay Madan, Christine T. Ferrara‐Cook, Deepak Dalvie, Lance Goulet, R. Scott Struthers, Alan S. Krasner   +6 more
wiley   +1 more source

No Placebo Effect beyond Regression to the Mean on the Six Minute Walk Test in Pulmonary Arterial Hypertension Trials. [PDF]

Int J Mol Sci, 2023
Anheyer D, Bugaj TJ, Lüdtke R, Appelbaum S, Trübel H, Ostermann T.   +5 more
europepmc   +1 more source

Placebo and placebo effects in medicine [PDF]

Journal of the Royal Society of Medicine, 2000
Michael Emmans Dean, Joseph S Conway
openaire   +2 more sources

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1352-1360, May 2025.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins, Miranda Davies, Elizabeth Lynn, Debabrata Roy, Alison Yeomans, Saad A. W. Shakir   +5 more
wiley   +1 more source

Correction to: Gender-Affirming Treatment of Gender Dysphoria in Youth: A Perfect Storm Environment for the Placebo Effect-The Implications for Research and Clinical Practice. [PDF]

Arch Sex Behav, 2023
Clayton A.
europepmc   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1306-1321, May 2025.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source